SynthesisDrug design, development and therapy2026
From Methotrexate Resistance to Biologic and Targeted Pharmacotherapy: A Decade of Phase 4 Clinical Trials Evidence in Rheumatoid Arthritis.
Synthesis in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) management; however, up to 30-40% of patients experience inadequate response or intolerance, necessitating escalation to advanced therapeutic strategies. Tumor necrosis factor (TNF) inhibitors were the first biologic agents introduced for RA and continue to play an important role in MTX-resistant disease, alongside newer biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs). Objective: To synthesize Phase 4 clinical trial evidence published between 2014 and 2024 evaluating therapeutic strategies for MTX-resistant RA, including TNF inhibitor optimization, newer biologic and targeted synthetic DMARDs, adjunctive therapies, and emerging precision medicine approaches. Methods: A systematic review of Phase 4 interventional trials registered on ClinicalTrials.gov was conducted using the keyword "rheumatoid arthritis", with predefined eligibility restrictions applied. Trials enrolling adults with MTX-resistant RA and reporting clinical, safety, biomarker, imaging, or patient reported outcomes were included. Extracted data encompassed study design, intervention type, trial classification (exploratory/mechanistic, optimization/treat to target, or effectiveness/safety), outcomes, and enrolment. Results: Eighteen Phase 4 trials were identified, encompassing a heterogeneous range of study designs and therapeutic strategies. Optimization and treat-to-target studies demonstrated continued clinical relevance of TNF inhibitors, particularly in combination with MTX. Newer biologic and targeted synthetic DMARDs showed comparable efficacy, while exploratory trials provided mechanistic insights through biomarker and imaging assessments. Safety profiles across trials were generally consistent with established class effects, with infections and laboratory abnormalities most frequently reported and no unexpected safety signals observed. Conclusion: Phase 4 evidence highlights the continued role of TNF inhibitors alongside newer biologic and targeted synthetic therapies in MTX-resistant RA. Trial heterogeneity reflects real world clinical complexity, underscoring the importance of treatment optimization, safety monitoring, and emerging precision strategies in contemporary RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.